This article summarized the latest R&D progress of Brompheniramine maleate, the Mechanism of Action for Brompheniramine maleate, and the drug target R&D trends for Brompheniramine maleate.

Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.

This article summarized the latest R&D progress of Lomustine, the Mechanism of Action for Lomustine, and the drug target R&D trends for Lomustine.

Oligonucleotides (ONs) are a class of drugs composed of single or double strands of oligonucleotides synthesized by artificial chemistry.

This article summarized the latest R&D progress of Vorinostat, the Mechanism of Action for Vorinostat, and the drug target R&D trends for Vorinostat.

Kite's Car T-cell Therapy Yescarta® exhibits a substantial treatment response rate and durable remission for patients with relapsed/resistant Large B-cell Lymphoma.

This article summarized the latest R&D progress of Voclosporin, the Mechanism of Action for Voclosporin, and the drug target R&D trends for Voclosporin.

Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), also known as CD152, is a transmembrane protein on the surface of T cells encoded by the CTLA-4 gene.

This article summarized the latest R&D progress of Vismodegib, the Mechanism of Action for Vismodegib, and the drug target R&D trends for Vismodegib.

Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.

This article summarized the latest R&D progress of Vildagliptin, the Mechanism of Action for Vildagliptin, and the drug target R&D trends for Vildagliptin.

Recombinant Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1A subfamily of the CYP1 family and is encoded by the CYP1A2 gene.